Innovations and Developments of Rituximab Biosimilar Market PR-BG.com (прессъобщения) (press release) November 21,2013 : Bharat Book Bureau presents the new report, on 'Therapy Class Overview : Rituximab biosimilar' assesses that Approval of Inflectra/Remsima, the first biosimilar Monoclonal antibody (Mab) from Celltrion and Hospira in EU in 2013 is a ... |
